Objectives: To compare the long-term efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) combined with concurrent antegrade embolization in treating portal hypertension with oesophagogastric variceal bleeding in patients with and without large spontaneous portosystemic shunts (L-SPSSs).
Materials And Methods: We retrospectively analysed data from patients with portal hypertension who underwent TIPS from November 2015 to April 2022. The patients were screened according to the inclusion criteria and were divided into L-SPSSs group (L-S group) and Non L-SPSSs group (Non L-S group). The primary outcome was the 2-year liver transplantation-free survival (TFS) rate. Secondary outcomes contained the incidence of overt hepatic encephalopathy (OHE), ectopic embolization and the 2-year rebleeding rate.
Results: A total of 259 patients were enrolled (64 patients in L-S group and 195 patients in Non L-S group). The average age was 57.2 years, and the success rate of procedure was 100%. Baseline data showed no significant differences between two groups. There was a statistically significant difference in the 2-year liver transplantation-free rate between two groups (L-S vs. Non L-S, 84.38% vs. 71.28%; p = 0.045). OHE occurred in 19 (29.69%) patients with L-SPSSs and 104 (53.33%) patients without L-SPSSs, with a statistically significant difference (p = 0.001). And no statistically significant difference was found in ectopic embolism incidence rate and the 2-year rebleeding rate between two groups. Multivariate Cox regression analysis identified male gender, portal vein thrombosis and preoperative high blood ammonia levels as independent risk factors for long-term survival.
Conclusion: Compared to Non L-S group, the patients in L-S group achieve longer liver transplantation-free survival and lower incidence rate of OHE without increasing the risk of 2-year rebleeding and ectopic embolization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1754-9485.13832 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What about anterior endocrowns?
Evid Based Dent
March 2025
Edinburgh Dental Institute Paediatric Department 39x Lauriston Building, Edinburgh, UK.
A Commentary On: Fehrenbach J, de Soares J L S, do Nascimento Foly J C S, Miotti L L, Münchow E A Mechanical performance of endocrown restorations in anterior teeth: A systematic review and network meta-analysis. Dent Mater 2025; https://doi.org/10.
View Article and Find Full Text PDFNivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.
Nat Med
March 2025
Bristol Myers Squibb, Princeton, NJ, USA.
First-line nivolumab-plus-chemotherapy demonstrated superior overall survival (OS) and progression-free survival versus chemotherapy for advanced gastroesophageal adenocarcinoma with programmed death ligand 1 combined positive score ≥ 5, meeting both primary end points of the randomized phase 3 CheckMate 649 trial. Nivolumab-plus-ipilimumab provided durable responses and higher survival rates versus chemotherapy; however, the prespecified OS significance boundary was not met. To identify biomarkers predictive of differential efficacy outcomes, post hoc exploratory analyses were performed using whole-exome sequencing and RNA sequencing.
View Article and Find Full Text PDFMechanical Thrombectomy in Prestroke Disability: Data From the Italian Endovascular Stroke Registry.
Stroke
March 2025
Emergency Department Stroke Unit, Department of Human Neurosciences, Sapienza University of Rome, Italy (D.T.).
Background: The benefits and safety of mechanical thrombectomy (MT) in patients with prestroke disability, classified as modified Rankin Scale (mRS) score of 3 to 4, and anterior circulation stroke remain uncertain. This study aims to evaluate these factors using data from the Italian Registry of Endovascular Treatment in Acute Stroke.
Methods: We analyzed data collected between 2015 and 2021, comparing functional outcomes (mRS), symptomatic intracerebral hemorrhage, and recanalization rates (Thrombolysis in Cerebral Infarction) at 90 days post-MT in patients with prestroke mRS score of 3 to 4 versus 0 to 2.
Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations.
Circ Heart Fail
March 2025
Center for Individualized and Genomic Medicine Research, Henry Ford Hospital, Detroit, MI (D.E.L.).
Background: We derived and validated proteomic risk scores (PRSs) for heart failure (HF) prognosis that provide absolute risk estimates for all-cause mortality within 1 year.
Methods: Plasma samples from individuals with HF with reduced ejection fraction (HFrEF; ejection fraction <40%; training/validation n=1247/762) and preserved ejection fraction (HFpEF; ejection fraction ≥50%; training/validation n=725/785) from 3 independent studies were run on the SomaScan Assay measuring ≈5000 proteins. Machine learning techniques resulted in unique 17- and 14-protein models for HFrEF and HFpEF that predict 1-year mortality.
Addressing the challenge of antimicrobial resistance.
Commun Med (Lond)
March 2025
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Antimicrobial resistance (AMR) is a global health challenge that requires cross-disciplinary collaboration to mitigate its impact on human health. We discuss some of the topical advances in the field, highlighting the AMR collection, which brings attention to the problem of AMR and suboptimal antimicrobial use in human medicine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!